Evidence map›Paper›PMID 36500178›Full record

ArticleMaterials (Basel, Switzerland)2022

In Vitro Transcriptome Analysis of Cobalt Boride Nanoparticles on Human Pulmonary Alveolar Cells.

Mehmet Enes Arslan, Arzu Tatar, Özge Çağlar Yıldırım, İrfan Oğuz Şahin, Ozlem Ozdemir, Erdal Sonmez, Ahmet Hacımuftuoglu, Metin Acikyildiz, Fatime Geyikoğlu, Adil Mardinoğlu and 1 more

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mehmet Enes ArslanDepartment of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, Erzurum 25050, Turkey.ORCID 0000-0002-1600-2305
Arzu TatarDepartment of Otorhinolaryngology, Faculty of Medicine, Ataturk University, Erzurum 25240, Turkey.
Özge Çağlar YıldırımDepartment of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, Erzurum 25050, Turkey.ORCID 0000-0003-1412-8411
İrfan Oğuz ŞahinDepartment of Pediatrics, Pediatric Cardiology, Faculty of Medicine, Ondokuz Mayıs University, Samsun 55139, Turkey.
Ozlem OzdemirDepartment of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, Erzurum 25050, Turkey.ORCID 0000-0002-5472-8174
Erdal SonmezAdvanced Materials Research Laboratory, Department of Nanoscience & Nanoengineering, Graduate School of Natural and Applied Sciences, Ataturk University, Erzurum 25240, Turkey.
Ahmet HacımuftuogluDepartment of Medical Pharmacology, Medical Faculty, Atatürk University, Erzurum 25240, Turkey.
Metin AcikyildizDepartment of Chemistry, Faculty of Science and Art, Kilis 7 Aralık University, Kilis 79000, Turkey.
Fatime GeyikoğluDepartment of Biology, Faculty of Arts and Sciences, Atatürk University, Erzurum 25240, Turkey.
Adil MardinoğluScience for Life Laboratory, KTH-Royal Institute of Technology, SE-17121 Stockholm, Sweden.ORCID 0000-0002-4254-6090
Hasan TürkezDepartment of Medical Biology, Faculty of Medicine, Atatürk University, Erzurum 25240, Turkey.

Funding

The National Boron Research Institute (BOREN) Ç0391
6 · The paper itself

Abstract

Nanobiotechnology influences many different areas, including the medical, food, energy, clothing, and cosmetics industries. Considering the wide usage of nanomaterials, it is necessary to investigate the toxicity potentials of specific nanosized molecules. Boron-containing nanoparticles (NPs) are attracting much interest from scientists due to their unique physicochemical properties. However, there is limited information concerning the toxicity of boron-containing NPs, including cobalt boride (Co

Indexed as

cobalt boride nanoparticlescytotoxicityhuman pulmonary alveolar epithelial cellsin vitropathway analysistoxicogenomics

Identifiers

PMID36500178
PMCPMC9740129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.